Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Financing Activities (2016 - 2026)

Heron Therapeutics filings provide 15 years of Cash from Financing Activities readings, the most recent being -$51000.0 for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 179.69% to -$51000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $14.3 million, a 1341.29% increase, with the full-year FY2025 number at $14.4 million, up 1434.79% from a year prior.
  • Cash from Financing Activities hit -$51000.0 in Q1 2026 for Heron Therapeutics, down from $219000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $74.9 million in Q3 2022 to a low of -$637000.0 in Q1 2022.
  • Median Cash from Financing Activities over the past 5 years was $315000.0 (2022), compared with a mean of $8.5 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 105652.11% in 2022 and later plummeted 179.69% in 2026.
  • Heron Therapeutics' Cash from Financing Activities stood at $439000.0 in 2022, then tumbled by 54.67% to $199000.0 in 2023, then soared by 112.56% to $423000.0 in 2024, then crashed by 48.23% to $219000.0 in 2025, then tumbled by 123.29% to -$51000.0 in 2026.
  • The last three reported values for Cash from Financing Activities were -$51000.0 (Q1 2026), $219000.0 (Q4 2025), and $13.4 million (Q3 2025) per Business Quant data.